Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages.

ABSTRACT: The advent of CAR T cells targeting CD19 or BCMA on B cell neoplasm demonstrated remarkable efficacy, but rapid relapses and primary refractoriness remains challenging. A leading cause of CAR T cell failure is their lack of expansion and limited persistence. Long-lived, self-renewing multipotent T memory stem cells (T_SCM) and T central memory cells (T_CM) likely sustain superior tumor regression, but their low frequencies in blood from cancer patients impose a major hurdle for clinical CAR T production. We designed a clinically compliant protocol for generating BCMA CAR T cells starting with increased T_SCM/T_CM cell input. A CliniMACS Prodigy process was combined with flow cytometry-based enrichment of CD62L⁺CD95⁺ T cells. Alt

SUBMITTER: Joedicke JJ 

PROVIDER: S-EPMC8791860 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature